Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.36 USD
+0.07 (5.43%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.36 USD
+0.07 (5.43%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Zacks News
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
by Zacks Equity Research
Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 3.85% and 4.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More
by Kinjel Shah
Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.
Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics
by Zacks Equity Research
Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics are part of the Zacks Screen of the Week article.
Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn
by Zacks Equity Research
The new restructuring plan will allow Nektar (NKTR) to extend its cash runway into mid-2026. The company plans to reduce its workforce by approximately 60%.
Forget Bargain Hunting, Buy 5 Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nektar Therapeutics (NKTR).
Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics
by Zacks Equity Research
Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Rebounds in 2023
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.
Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Upgraded to Buy: Here's Why
by Zacks Equity Research
Nektar (NKTR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -69.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Nektar (NKTR)
by Zacks Equity Research
Nektar (NKTR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of 21.13% and 66.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Concert (CNCE) Moves 19.3% Higher: Will This Strength Last?
by Zacks Equity Research
Concert (CNCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Nektar (NKTR) reports encouraging third-quarter 2022 results. The narrower-than-expected loss is on account of lower operating expenses incurred during the quarter.
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 48.94% and 1.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar Therapeutics (NKTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH